Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Entecavir salt compound, preparation method and medicine application thereof

A technology of entecavir and compound, which is applied in the pharmaceutical field to achieve the effects of good stability, improved water solubility and good water solubility

Active Publication Date: 2010-07-21
FUJIAN COSUNTER PHARMA CO LTD
View PDF9 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Chinese patent application 200510097848.1 discloses addition salt compounds such as maleate and tartrate of entecavir; Chinese patent application 03135304.5 discloses metal ion salts such as sodium salt and potassium salt of entecavir. Charge transfer occurs, so that the carbonyl group in the entecavir structure becomes a sodium alkoxide or potassium alkoxide group, which changes the original structural form of entecavir, which may bring adverse effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Entecavir salt compound, preparation method and medicine application thereof
  • Entecavir salt compound, preparation method and medicine application thereof
  • Entecavir salt compound, preparation method and medicine application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Add 10ml of methanol, 1.0g of entecavir and 0.62g of p-toluenesulfonic acid into a 25ml eggplant-shaped bottle, stir, heat to reflux for 4h, cool to room temperature, evaporate part of the solvent under reduced pressure, cool the residue to 0°C, filter with suction, and dry in vacuo , an off-white solid was obtained, which was recrystallized from methanol to obtain 1.2 g of white crystalline entecavir p-toluenesulfonate, with a yield of 74.1%.

[0056] IR(KBr)cm -1 :

[0057] 3388, 3333, 3191, 3137, 3100~2800, 2925, 1708, 1641, 1603, 1556, 1533, 1474, 1411, 1374, 1169, 1122, 1033, 1009.

[0058] 1 HNMR (DMSO-d 6 )δ:

[0059] 11.48 (brs, 1H, D 2 Disappeared after O exchange), 9.04 (s, 1H), 7.51 (d, 2H), 7.13 (d, 2H), 7.00~7.80 (brs, 5H, D 2 O disappears after exchange), 5.51~5.48(m, 1H), 5.23(m, 1H), 4.85(m, 1H), 4.26(m, 1H), 3.54~3.60(m, 2H), 2.56(m, 1H ), 2.31~2.35(m, 1H), 2.29(s, 3H), 2.15~2.17(m, 1H).

[0060] 13 CNMR (DMSO-d 6 ):

[0061] 155.43, 153.90, ...

Embodiment 2

[0065] Add 35ml of water, 1.0g of entecavir and 0.62g of p-toluenesulfonic acid into a 50ml reaction flask, stir, react at 80°C for 2h, cool to room temperature, evaporate the solvent under reduced pressure, and recrystallize the residue with methanol to obtain white crystals of p-toluenesulfonate Entecavir acid 1.3g, yield 80.2%.

Embodiment 3

[0067] Add 30ml of ethanol, 2.0g of entecavir and 1.25g of p-toluenesulfonic acid into a 50ml eggplant-shaped bottle, stir, heat to reflux for 3h, cool to room temperature, evaporate part of the solvent under reduced pressure, cool the residue to 0°C, filter with suction, and dry in vacuo , an off-white solid was obtained, which was recrystallized from ethanol to obtain 2.0 g of white crystalline entecavir p-toluenesulfonate, with a yield of 61.7%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
water solubilityaaaaaaaaaa
Login to View More

Abstract

The invention provides entecavir acid addition salt compound, in particular relates to addition salt of toluene sulfonic acid (including para-, iso- and o- of methyl in benzene ring) and entecavir, a preparation method and medicine application thereof; the specific preparation method is that: under the condition with the temperature between room temperature and solvent backflow temperature, the entecavir and toluenesulfonic acid are contacted in solvent and are reacted to form salt, and then salt crystallization is carried out under the room temperature condition or at the temperature lower than the room temperature, extraction filtration, water pumping after washing is carried out and drying are carried out to obtain the entecavir toluene sulfonic acid, or the hydrate of the entecavir toluene sulfonic acid; and the invention further relates to the application of the entecavir toluene sulfonic acid to the medicines.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and relates to a derivative salt compound of Entecavir, specifically an addition salt compound of Entecavir, a preparation method thereof and their application in medicine. technical background [0002] Entecavir is a guanosine analogue with the chemical name 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylenecyclopentyl ]-1,9-dihydro-6H-purin-6-one, the molecular structure is as follows: [0003] Molecular formula C12H15N5O3, molecular weight 277.3, usually use its monohydrate, molecular formula C12H15N5O3.H2O, molecular weight 295.3. [0004] Entecavir is a highly effective antiviral agent. Clinical studies have shown a good inhibitory effect on hepatitis B virus. Due to the high activity of entecavir against hepatitis B virus, a very low dose is enough to achieve the desired therapeutic effect. Generally, adults take it orally every day 0.5mg or 1mg entecavir can achieve a good th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D473/18C07C309/30A61K31/522A61P1/16A61P31/20
Inventor 康惠燕陈国华
Owner FUJIAN COSUNTER PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com